68Ga-FAPI-46 PET/CT用于PSMA低表达的转移性去势抵抗性前列腺癌患者
一例70岁mCRPC患者因低PSMA表达行68Ga-FAPI-46 PET/CT评估FAPI靶向放射性配体治疗资格,68Ga-PSMA与68Ga-FAPI PET/CT在病灶可检测性和SUV上存在不一致,提示68Ga-FAPI诊疗一体化可能对PSMA表达不显著或177Lu-PSMA治疗失败后的mCRPC有潜在作用。
要点
- 70岁mCRPC患者因低PSMA表达行68Ga-FAPI-46 PET/CT评估FAPI靶向治疗资格。
- 68Ga-PSMA与68Ga-FAPI PET/CT在病灶可检测性和SUV上存在不一致。
- 68Ga-FAPI诊疗一体化可能对PSMA表达不显著或177Lu-PSMA治疗失败后的mCRPC有潜在作用。
核心结论
- 68Ga-FAPI诊疗一体化可能对PSMA表达不显著或177Lu-PSMA治疗失败后的mCRPC患者治疗有潜在作用。
研究设计与样本
- 一例70岁mCRPC患者因再分期及177Lu-PSMA靶向分子放射性配体治疗可能性转诊行68Ga-PSMA PET/CT。
主要发现
- 68Ga-PSMA PET/CT显示多发68Ga-PSMA亲和骨转移灶,SUV低。
- 因PSMA低表达行68Ga-FAPI-46 PET/CT评估FAPI靶向放射性配体治疗资格,68Ga-PSMA与68Ga-FAPI PET/CT在病灶可检测性和SUV上存在不一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 70-year-old man with mCRPC (metastatic castration-resistant prostate cancer) was referred for 68 Ga-PSMA PET/CT for restaging and the possibility of targeted molecular radioligand therapy with 177 Lu-PSMA. Numerous 68 Ga-PSMA-avid skeletal metastases with low SUVs were noted. Because of low PSMA expression, a 68 Ga-FAPI-46 PET/CT was performed to evaluate the eligibility for FAPI-based radioligand therapy. There were some discordant findings between 68 Ga-PSMA and 68 Ga-FAPI PET/CT scans regarding the detectability of lesions and SUVs. Our case signifies that 68 Ga-FAPI theragnostic may have a potential role in the treatment of mCRPC patients with insignificant PSMA expression or in cases after the failure of 177 Lu-PSMA therapy.
引用
- Aryana K, Manafi-Farid R, Amini H, et al. 68 Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression. Clin Nucl Med. 2022. PMID: 35777753. doi:10.1097/RLU.0000000000004315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。